Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Fortress Biotech Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
FBIO
Nasdaq
2836
https://www.fortressbiotech.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Fortress Biotech Inc
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
- Apr 25th, 2024 12:30 pm
Avenue Therapeutics Announces Reverse Stock Split
- Apr 24th, 2024 11:30 am
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
- Apr 11th, 2024 4:24 pm
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
- Mar 28th, 2024 8:05 pm
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
- Mar 28th, 2024 1:00 pm
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
- Mar 25th, 2024 12:30 pm
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
- Mar 22nd, 2024 12:30 pm
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
- Mar 21st, 2024 8:01 pm
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
- Mar 18th, 2024 8:05 pm
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
- Mar 18th, 2024 12:30 pm
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
- Mar 18th, 2024 12:00 pm
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
- Mar 15th, 2024 12:30 pm
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
- Mar 15th, 2024 12:15 pm
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
- Mar 13th, 2024 12:30 pm
Fortress Biotech to Participate in 36th Annual ROTH Conference
- Mar 12th, 2024 12:30 pm
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
- Mar 11th, 2024 12:30 pm
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
- Mar 11th, 2024 12:00 pm
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
- Mar 7th, 2024 12:30 pm
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
- Mar 4th, 2024 1:30 pm
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
- Feb 22nd, 2024 1:30 pm
Scroll